Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mayo Clinic / University of Minnesota Prostate SPORE

Award Number: P50CA298941
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/18/2026
PERIOD OF PERFORMANCE END DATE: 08/31/2031

Group Awards By:

View Award Description

Mayo Clinic / University of Minnesota Prostate SPORE - SUMMARY / ABSTRACT – Overall Component The Mayo Clinic–University of Minnesota SPORE in Prostate Cancer (Mayo/UMN Prostate SPORE) is a revised (A1) application that uniquely combines resources and expertise in prostate cancer translational research at two NCI-designated Comprehensive Cancer Centers: the Mayo Clinic Comprehensive Cancer Center (MCCCC, with locations in Rochester–MN, Phoenix–AZ, and Jacksonville–FL) and the University of Minnesota Masonic Cancer Center (MCC, in Minneapolis). This is a revised SPORE submission that is led by two internationally recognized experts in prostate cancer research, Drs. Elisabeth Heath (clinical/translational science–Mayo) and Emmanuel Antonarakis (clinical/translational science–UMN), as well as two exceptional lab-based co-investigators, Drs. Josep Domingo-Domenech (basic/translational science–Mayo) and Scott Dehm (basic/translational science– UMN), who together bridge the gap between clinical and laboratory sciences. The overall goal of the Mayo/UMN Prostate SPORE is to decrease the morbidity and mortality associated with metastatic castration-resistant prostate cancer (mCRPC) by making discoveries that address critical questions in prostate cancer tumor biology and novel therapeutics. We anticipate that our research will lead to the development of transformative new interventions for the treatment of advanced prostate cancer. This Mayo/UMN Prostate SPORE application consists of four (4) Translational Research Projects led by teams of outstanding clinical and laboratory-based investigators with clear records of accomplishment in prostate cancer research. The overarching theme of our SPORE Projects is to develop novel molecularly-targeted therapeutics for patients with metastatic castration- resistant prostate cancer (mCRPC). In this spirit, our 4 multidisciplinary Projects are: Project 1: Targeting TP53- altered castration-resistant prostate cancer with bipolar androgen therapy (BAT) plus carboplatin; Project 2: Harnessing synthetic lethality in DNA replication stress for SPOP-mutated castration-resistant prostate cancer; Project 3: Targeting B7-H3 using tri-specific killer engagers (TriKE) to treat metastatic castration-resistant prostate cancer; and Project 4: The synergy of PARP inhibition plus Aurora kinase inhibition in advanced prostate cancer therapy. These four projects will be complemented by two outstanding Career Enhancement and Developmental Research Programs (CEP and DRP). In turn, these projects and programs will be further supported by strong institutional commitments of “matching funds” ($3 million over 5 years) and research space, as well as three critical cores: an Administrative Core (Core A), a Biospecimen/Pathology Core (Core B), and a Biostatistics/Bioinformatics Core (Core C). The Mayo/UMN Prostate SPORE seeks to establish a formal research partnership between Mayo and UMN by uniquely combining the complementary strengths, collaborative infrastructure, and deliberate pairing of multi-institutional clinical trial and basic science leadership to accelerate prostate cancer discoveries and therapies, shape national treatment strategies to advance patient care (together with our patient advocates), and develop the next generation of prostate cancer investigators.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $2,235,791 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Centers Support Grants	000	1	9/17/2026	NEW	$2,235,791
														Subtotal = $2,235,791

Grand Total All Awards = $2,235,791

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mayo Clinic / University of Minnesota Prostate SPORE

Award Number: P50CA298941

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/18/2026

PERIOD OF PERFORMANCE END DATE: 08/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer